Menu
Back to Journals » Infection and Drug Resistance » Volume 4
Current treatment of choice for chronic hepatitis C infection
Authors Yasin T, Riley T, Schreibman I
Published 12 January 2011 Volume 2011:4 Pages 11—18
DOI https://doi.org/10.2147/IDR.S4827
Review by Single anonymous peer review
Peer reviewer comments 4
Tareq Yasin, Thomas R Riley, Ian R Schreibman
Penn State Hershey Medical Center and College of Medicine, Pennsylvania, USA
Abstract: More than three million Americans have chronic hepatitis C infection, and the disease remains one of the most common blood-borne infections in the US. Treatment is focused on the chronic form of the disease, because the acute one tends to be self-limiting. In this article, we review the recent literature regarding the most effective therapy against hepatitis C infection, to confirm the current treatment of choice for the disease. We conclude that combination therapy with pegylated interferon and ribavirin remains the initial treatment of choice. New research focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early data that appear to be promising.
Keywords: hepatitis C virus, infection, chronic, treatment, pegylated interferon, ribavirin
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.